A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t working, but it’s not without risk.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and content measurement, audience insights and product development. List of Partners (vendors)

A new study has found small amounts of liquid ketamine administered in a clinical setting can significantly reduce symptoms of post-traumatic stress disorder, with fewer side effects.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

A clinic in Arapahoe County is exploring new ways to help patients by offering ketamine-assisted psychotherapy.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year than those who reported no past-year drug use.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of research suggesting it can be especially effective against types

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.